Morphic Holding, Inc. (MORF)
Stock Price:
$25.79 USD
-0.19 (-0.73%)
Updated Jul 6, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
790.39M |
| Revenue (ttm) |
16.50M |
| Net Income (ttm) |
-54.87M |
| Shares Out |
30.60M |
| EPS (ttm) |
-2.37 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 6, 2020 |
| Last Price |
$25.79 |
| Previous Close |
$25.98 |
| Change ($) |
-0.19 |
| Change (%) |
-0.73% |
| Day's Open |
26.48 |
| Day's Range |
25.43 - 26.48 |
| Day's Volume |
62,155 |
| 52-Week Range |
9.90 - 33.50 |
More Stats
| Market Cap |
790.39M |
| Enterprise Value |
571.10M |
| Earnings Date (est) |
Aug 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
30.60M |
| Float |
9.30M |
| EPS (basic) |
-6.21 |
| EPS (diluted) |
-2.37 |
| FCF / Share |
-2.08 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
559,637 |
| Short Ratio |
8.40 |
| Short % of Float |
4.79% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
47.89 |
| PB Ratio |
5.48 |
| Revenue |
16.50M |
| Operating Income |
-58.64M |
| Net Income |
-54.87M |
| Free Cash Flow |
-62.68M |
| Net Cash |
219.29M |
| Net Cash / Share |
7.16 |
| Gross Margin |
-222.72% |
| Operating Margin |
-355.35% |
| Profit Margin |
-332.50% |
| FCF Margin |
-379.79% |
| ROA |
-17.48% |
| ROE |
-52.08% |
| ROIC |
-60.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$29.67*
(15.04% upside)
Low
28.0
Current: 25.79
High
31.0
Target: 29.67
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 16.98 | 3.36 | - |
| Revenue Growth | 405.57% | - | - |
| Gross Profit | 16.98 | 3.36 | - |
| Operating Income | -46.99 | -24.63 | -16.93 |
| Net Income | -43.33 | -23.83 | -16.92 |
| Shares Outstanding | 16.10 | 1.07 | 1.01 |
| Earnings Per Share | -2.69 | -22.28 | - |
| Operating Cash Flow | -41.65 | 76.34 | -15.42 |
| Capital Expenditures | -2.16 | -0.66 | -0.91 |
| Free Cash Flow | -43.81 | 75.68 | -16.32 |
| Cash & Equivalents | 237 | 186 | 21.03 |
| Total Debt | - | - | 0.63 |
| Net Cash / Debt | 237 | 186 | 20.40 |
| Assets | 247 | 189 | 23.24 |
| Liabilities | 107 | 102 | 3.25 |
| Book Value | 141 | -52.55 | -29.69 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Morphic Holding, Inc. |
| Country |
United States |
| Employees |
80 |
| CEO |
Praveen P. Tipirneni |
Stock Information
| Ticker Symbol |
MORF |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: MORF |
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidates in clinical development are MORF-720, a selective oral avß6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC); and MORF-057, a a4ß7 specific integrin inhibitor for the treatment of inflammatory bowel disease (IBD). The company is also developing MR ß6 #2, a selective avß6 specific integrin inhibitor to treat IPF and PSC; and avß1 integrin for the treatment of fibrosis. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. The company was founded in 2014 and is based in Waltham, Massachusetts.